Latest From Biotech Now

Debt, Taxes and Politics: Is There a Way Out?

Debt, Taxes and Politics: Is There a Way Out?

BIO President and CEO Jim Greenwood kicked off a keynote discussion with Sen. Alan Simpson and Erskine Bowles at the BIO International Convention, saying public policy can make or break the biotech industry’s best efforts to deliver innovations that make our world a better place, and then asked the esteemed duo if our government can make the tough choices needed to keep our economy strong. “You can’t tax your way out of this hole, you can’t cut spending your Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Neal Carter on Ag Biotech: It’s Not An Experiment Anymore

Neal Carter on Ag Biotech: It's Not An Experiment Anymore

BIO International Convention attendees filled the Food & Agriculture Pavilion on the Show Floor Wednesday to hear Dr. Neal Carter of Okanagan Specialty Fruits give a presentation he delivered at a TEDx event last October in Penticton, BC on the value of biotechnology in agriculture. Okanagan Specialty Fruits has developed a non-browning apple known as the Arctic Apple  - just one of the many examples of ways biotechnology is improving agriculture. After spending many years as a farmer in Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Spotlight on China

Cho

The 20th annual BIO International Convention is wrapping up in Chicago. Experts and leaders from leading global biotechnology, biologics and investment companies gathered together to discuss the opportunities and challenges in the biologics industry. A large China Food and Drug Administration (CFDA) delegation led by Deputy Commissioner Bian Zhenjia participated in a half-day session dedicated to developing a world-class therapeutic biologics industry in China. There has been a shift in recent years in the usage Read More >

Business and Investments  |  1 Comment  |  Email This Post
Tags: , , , ,

The Rise of Specialty Pharmaceuticals

Albert Thigpen

Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, it’s estimated they’ll account for nearly half of the 100 top-selling medications on the market. With an average cost for a specialty medical therapy hovering around $35,000 to $75,000 per patient per year, this is an area that is getting the attention of top industry players – from biopharma who see the market opportunity to healthcare payors like health plans Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

State of the Biotech Industry: Burrill’s Biotech 2013 Report

Burrill

To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of attendees in the audience, saying after 45 years in the biotech industry, 27 years authoring the Burrill State-of-the-Industry Report and 20 years of presenting the report at Convention, he was determined to get through 228 slides in 90 minutes. And, he delivered, providing a comprehensive snapshot of the industry Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,